-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $71

Benzinga·10/15/2026 21:57:56
语音播报
UBS analyst Joon Lee initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $71.